2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, CML, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

5071 Rapid and deep molecular responses by next-generation sequencing following subcutaneous blinatumomab

Elias Jabbour, MD, Federico Lussana2, Anna Torrent, MD3, Pilar Martinez Sanchez, MD, PhD4, Mar Tormo Sr, MD5, Vaibhav Agrawal6, Thomas Cluzeau, MD, PhD7, Francoise Huguet, MD8, Vladan Vucinic, MD9, Sabina Chiaretti, MD10, Mary Lynn Savoie11, Andre C. Schuh Sr, BSc, MD, FRCPC12, Stefan Schwartz, MD13, Cristina Papayannidis, MD, PhD14, Takuya Miyazaki15, Takayuki Ikezoe, MD, PhD16, Jesus Maria Hernandez Rivas, MD17, Ryan D. Cassaday, MD18, Maher Abdul-Hay, MD19, Yuliya Katlinskaya20, Shekar Sunkoju21, Erin Guest, MD22, Hagop Kantarjian, MD23
1 The University of Texas MD Anderson Cancer Center, Houston, United States
2 Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy, University of Milan, Milan, Italy
3 Institut Català d'Oncologia, Institut de Recerca contra la Leucèmia Josep Carreras, Hospital Germans Trias i Pujol, Badalona, Spain, Universitat Autònoma de Barcelona, Barcelona, Spain
4 Hospital Universitario 12 de Octubre, Madrid, Spain
5 Hospital Clínico Universitario de Valencia, Instituto de Investigación Sanitaria INCLIVA, Valencia, Spain
6 Gehr Family Center for Leukemia Research, City of Hope National Medical Center, Duarte, United States
7 Université Côte d'Azur, CHU de Nice, Nice, France
8 Univ Toulouse, CHU Toulouse, IUCT-Oncopole, service d'Hématologie, Toulouse, France
9 Universitätsklinikum Leipzig, Leipzig, Germany
10 Sapienza University of Rome, Rome, Italy
11 Arthur J E Child Comprehensive Cancer Center, University of Calgary, Calgary, Canada
12 Princess Margaret Cancer Centre, Toronto, Canada
13 Charité – Universitätsmedizin Berlin, corporate member of Freie Universität and Humboldt-Universität zu Berlin, Berlin, Germany
14 IRCCS, Azienda Ospedaliero Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Bologna, Italy
15 Yokohama City University Medical Center, Kanagawa, Japan
16 Fukushima Medical University School of Medicine, Fukushima, Japan
17 Cancer Research Center (IBMCC) CSIC, University of Salamanca, Salamanca, Spain
18 University of Washington School of Medicine and Fred Hutchinson Cancer Center, Seattle, United States
19 Laura and Isaac Perlmutter Cancer Center at New York University Langone Health, New York, United States
20 Amgen Inc., Thousand Oaks, United States
21 Amgen India, Hyderabad, India
22 Amgen Inc., Thousand Oaks, United States
23 The University of Texas MD Anderson Cancer Center, Houston, United States

Introduction

Measurable residual disease (MRD) response is a pivotal marker endpoint for relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) and a key prognostic factor for blinatumomab (blin) treatment (Gökbuget N, et al. Blood Adv. 2019; Brown P, et al. Br J Haematology. 2020). Results from the dose escalation and dose expansion portion of the multicenter, single arm, phase 1 study of subcutaneous (SC) blin (NCT04521231) demonstrated an acceptable safety profile and high efficacy of 2 selected doses in patients with R/R B-ALL (Jabbour et al, Lancet Haematol. 2025). Here, we evaluated the depth and kinetics of MRD clearance at the lowest dose tested in phase 1 expansion in cases for which Cycle 1 Day 12 (C1D12) MRD data were available. We assessed early MRD reduction using highly sensitive next-generation sequencing (NGS), supplemented by central polymerase chain reaction (PCR) and local testing.

Methods

Adults with R/R B-ALL who received single-agent SC blin injection (0.3–0.6 mL) at a dose of 250 μg once-daily for week 1, followed by 500 μg thrice-weekly (250- μg/500- μg cohort) were included in this analysis. Each cycle included 4 weeks of treatment followed by a 1-week treatment-free interval. Patients were to receive 2–5 cycles. MRD was assessed using available central (NGS; Adaptive clonoSEQ® and PCR) and local methods. Patients with valid test results (MRD response [< 10⁻⁴]/non-response [≥ 10⁻⁴]) by central NGS, central PCR, and/or local testing on C1D12 were included. In addition, patients who discontinued treatment on or before C1D12 were included using the first available post-baseline MRD assessment, regardless of the scheduled visit window. MRD response was determined using the most sensitive available assessment, prioritizing central NGS, then central PCR, and finally local MRD evaluation. MRD response vs non-response was assessed across available methods, whereas deep MRD response (< 10⁻⁶) was evaluated only among patients with central NGS assessments. Among patients who did not achieve MRD < 10–4 at C1D12, MRD kinetics were subsequently evaluated sequentially. The proportion of patients achieving MRD < 10–4 by Cycle 1 Day 27 (C1D27) was first assessed; among those remaining ≥ 10–4 at C1D27, the proportion achieving MRD < 10–4 by Cycle 2 Day 27 (C2D27) was subsequently evaluated.

Results

As of November 13, 2025, 20 patients (median age: 46 years; female: 35%) were included based on evaluable MRD assessment at C1D12, including 2 patients who discontinued treatment prior to C1D12 but remained assessable for MRD (1 patient assessed during safety follow-up after Day 12 and the other on Day 10). At baseline, patients had received a median of 1.5 prior lines of therapy (range, 1–5). Median pre-treatment bone marrow blast percentage was 68% (range, 5%–99%). Patients completed a median of 2 cycles (range, 0–5). Median duration of treatment was 51 days (range, 1–131).

MRD status (response vs non-response using the 10⁻⁴ cutoff) on C1D12 was evaluable in 55% (11/20), 65% (13/20), and 80% (16/20) patients by central NGS, central PCR, and local testing, respectively. Using a hierarchical patient-level assessment based on the most sensitive available assay, MRD response (< 10–4) by C1D12 was observed in 90% of patients (18/20), where local MRD results were not used to override central results and central PCR was not used to override central NGS. MRD response rates on C1D12 were 81.8% (9/11), 69.2% (9/13), and 87.5% (14/16) by central NGS, central PCR, and local testing, respectively. Among patients assessed by central NGS, 27.3% (3/11) achieved deep MRD response
(< 10–6) on C1D12.

Among 2 patients with MRD non-response at C1D12, 1 (50%) achieved MRD response (< 10–4) by C1D27 and 1 (50%) by C2D27, as assessed by central NGS in both the cases. All (100%) patients achieved MRD response by C2D27.

Conclusions

SC blin induced rapid molecular clearance with deep responses, with most patients achieving MRD < 10–4 by C1D12 by central NGS. Deep responses of < 10–6 were observed in a subset of patients by C1D12. Patients without MRD response at C1D12 who continued SC blin treatment demonstrated conversion to MRD response at subsequent assessments. These findings highlight the rapid kinetics of molecular response with SC blin, with continued deepening of responses during the first 2 treatment cycles, informing interpretation of early MRD assessments in ongoing and future studies.
Elias Jabbour, MD: Ascentage - Honoraria; Pfizer - Honoraria; Takeda - Honoraria; Amgen Inc. - Honoraria; Taiho - Honoraria; Novartis - Honoraria; TGRX Pharmaceuticals - Honoraria; Adaptive Biotechnologies - Honoraria; AbbVie - Honoraria; Gilead/Kite - Honoraria; TERN - Honoraria; Autolus - Honoraria; Amgen Inc. - Research Funding; AbbVie - Research Funding; Autolus - Research Funding; Takeda - Research Funding; Pfizer - Research Funding; Taiho - Research Funding; TGRX Pharmaceuticals - Research Funding; Gilead/Kite - Research Funding; Ascentage - Research Funding; Allotera - Research Funding; Novartis - Research Funding; Adaptive Biotechnologies - Research Funding; TERN - Research Funding; Amgen Inc. - Consultancy (Includes expert testimony); Allotera - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); TGRX Pharmaceuticals - Consultancy (Includes expert testimony); Autolus - Consultancy (Includes expert testimony); Adaptive Biotechnologies - Consultancy (Includes expert testimony); Ascentage - Consultancy (Includes expert testimony); Gilead/Kite - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Taiho - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); TERN - Consultancy (Includes expert testimony)